WebJ Clin Oncol. 2024; 37: 2815-2824. Crossref; PubMed; Scopus (116) ... Lancet Oncol. 2024; 21: 1433-1442. Summary; Full Text; Full Text PDF; PubMed; Scopus (184) Google Scholar ... Sehn LH ; et al. Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose ... WebApr 13, 2024 · Introduction. Diffuse large B-cell lymphoma (DLBCL) is characterized by the malignant proliferation of mature B-lymphocytes. It is the most common subtype of Non-Hodgkin’s lymphoma worldwide accounting for 30%-40% of all newly diagnosed cases. 1 DLBCL is categorized according to morphology, immunohistochemical, and molecular …
Polatuzumab Vedotin in Previously Untreated Diffuse …
WebMar 12, 2024 · Clinical Presentation and Diagnostic Tests. A 47-year-old man with class 3 (severe) obesity, body mass index of 51, obstructive sleep apnea, hypertension, and … WebMar 3, 2024 · Dr. Sehn reports receiving advisory board fees from AbbVie, AstraZeneca, Gilead, Genentech, Janssen, Merck, Takeda, Apobiologix, Acerta, Celgene, Kite, … castellani christian kikourou
Single-Agent Mosunetuzumab Shows Durable Complete …
WebApr 13, 2024 · BackgroundOvarian cancer is one of the most common female malignancies worldwide, and metabolic factors, such as hyperglycemia, are becoming potential risk factors. This study aimed to analyze the disease burden and its changing trend of ovarian cancer attributable to hyperglycemia in the Chinese population from 1990 to … Web23 hours ago · Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma. 1 Rituximab, an anti-CD20 monoclonal antibody, in combination with chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) is the current standard front-line therapy for advanced-stage … WebJan 19, 2024 · G.K., J.H., and L.M. are employees of F. Hoffmann–La Roche Ltd./Genentech, Inc.; and report ownership interests in F. Hoffmann–La Roche Ltd./Genentech, Inc. Y.M.C. … loan ekma